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§Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MassachusettsABSTRACT The mucus barrier is selectively permeable to a wide variety of molecules, proteins, and cells, and establishes
gradients of these particulates to influence the uptake of nutrients, the defense against pathogens, and the delivery of drugs.
Despite its importance for health and disease, the criteria that govern transport through the mucus barrier are largely unknown.
Studies with uniformly functionalized nanoparticles have provided critical information about the relevance of particle size and net
charge for mucus transport. However, these particles lack the detailed spatial arrangements of charge found in natural mucus-
interacting substrates, such as certain viruses, which may have important consequences for transport through the mucus
barrier. Using a novel, to our knowledge, microfluidic design that enables us to measure real-time transport gradients inside
a hydrogel of mucins, the gel-forming glycoprotein component of mucus, we show that two peptides with the same net charge,
but different charge arrangements, exhibit fundamentally different transport behaviors. Specifically, we show that certain con-
figurations of positive and negative charges result in enhanced uptake into a mucin barrier, a remarkable effect that is not
observed with either charge alone. Moreover, we show that the ionic strength within the mucin barrier strongly influences trans-
port specificity, and that this effect depends on the detailed spatial arrangement of charge. These findings suggest that spatial
charge distribution is a critical parameter to modulate transport throughmucin-based barriers, and have concrete implications for
the prediction of mucosal passage, and the design of drug delivery vehicles with tunable transport properties.INTRODUCTIONThe mucus barrier is a glycoprotein gel that coats all wet
surfaces in the human body, including the respiratory,
gastrointestinal, and urogenital tracts. The mucus barrier
has critical but poorly understood functions in protecting tis-
sues from attacks by pathogens and toxins, while facilitating
transport of beneficial particulates such as nutrients, oxy-
gen, and sperm (1–4). The selective permeability properties
of mucus have important roles in health and disease, and
changes in the structure or properties of mucus can result
in diseases ranging from dental cavity formation, cystic
fibrosis, viral and parasitic infections, to some forms of
infertility (5–9).
Little is known about the detailed molecular properties
that distinguish particles that permeate, or are rejected by,
a defined mucus barrier. Mucus is a complex mixture of
lipids, organic components, inorganic ions, enzymes, bacte-
ricidal proteins, and the mucin glycoproteins. Mucins are
the main gel-forming building blocks of mucus and are
composed of threadlike core proteins, which contain large
numbers of O-linked oligosaccharide chains that protrude
outward. The oligosaccharide chains confer negative
charge to the mucins through carboxyl and sulfate groups.
The mucin protein backbone and sugars create a plethora
of binding sites for many different incoming and secreted
particles and cells. Our inability to predict mucus passage
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toxins is related to our poor mechanistic and quantitative un-
derstanding of how natural substrates with complex charge
and hydrophobic surface properties interact with mucins.
Several studies have probed the selection criteria of the
mucus barrier, using both native mucus and hydrogels
from purified mucins as model systems, with uniformly
functionalized nanoparticles (10–20). These studies have
provided critical information about the relevance of particle
size and net charge for mucus transport. However, these par-
ticles lack the rich biochemistry of natural mucus-interact-
ing substrates, which contain charged and hydrophobic
surface domains as well as specific peptide sequences in
detailed spatial arrangements that may have evolved to
achieve productive interactions with the mucus (21,22).
Consequently, predictions of mucosal passage are difficult
to achieve because current models are simplistic and fail
to integrate the spatial and biochemical complexity found
in natural mucus-substrate interactions. A detailed under-
standing of the parameters that determine fast versus slow
passage through mucus will help set priorities for the design
criteria of mucus-penetrating particles with targeting abili-
ties, and, moreover, will provide new, to our knowledge,
design strategies beyond the narrow focus on net charge
or size of nanoparticles.
Here, we use easy-to-manipulate peptides for a system-
atic evaluation of microscopic surface combinations for
particulate passage through a barrier of mucins. As a well-
defined model for native mucus we use hydrogels generated
from the natively purified mucin pig gastric MUC5AC.http://dx.doi.org/10.1016/j.bpj.2013.07.050
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in gastric mucus, but is also a key constituent of cervical
and airway mucus (2) and hence contributes to the mucus
properties in these important anatomical locations. Hydro-
gels built from purified mucins have an important advantage
over native mucus: they can be generated under defined con-
ditions and with consistent properties, allowing repetitions
of experiments under reproducible conditions. This is diffi-
cult to achieve with native mucus from individuals, which
varies widely due to physiological differences between indi-
vidual patients (onset of illness, age, nutrition, etc.). More-
over, MUC5AC-based hydrogels have proven valuable for
the investigation of mucin gelation properties (24), microbi-
al behavior in the mucus layer (25,26), and recreate critical
permeability properties of native mucus toward nanopar-
ticles (19,20) and protons (27).
We have engineered a microfluidic system, which allows
for the detailed quantification of the partitioning and trans-
port gradients of peptides (and nanoparticles) into a mucin-
based barrier. Using these tools, we show that a combination
of positive and negative surface charges leads to nonadditive
effects on transport, and that nanoscale differences in the
spatial charge configuration of the peptide surface can signif-
icantly affect the rate of transport. We also show that such
selective transport is sensitive to ionic strength in the mucin
barrier. These results significantly improve our understand-
ing of the basic principles that govern selective transport
through the mucin barrier, and have implications for the
design of drug delivery vehicles for mucosal targeting.MATERIALS AND METHODS
Mucin purification and sample preparation
Mucins were purified from scrapings of fresh pig stomachs according to the
method developed by Gong et al. (28), with the difference that the cesium
chloride density gradient centrifugation was omitted. Lyophilized mucins
were reconstituted at 0.5% (w/v) in reconstitution buffer containing NaCl
and Hepes (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). Three
NaCl/Hepes concentrations were used, including 5 mM NaCl/5 mMHepes,
20 mM NaCl/20 mM Hepes, and 200 mM NaCl/20 mM Hepes. The recon-
stitution buffers used in all experiments were titrated to pH 7 using 6 M
NaOH before dissolving of the mucins, and 0.0007% (w/v) of 500 nm fluo-
rescent polystyrene microspheres (Polysciences, Warrington, PA) were
added to the reconstituted mucin solution as a fluorescent tracer to track
the flow of the mucins during microfluidic device filling. Hepes buffer at
20 mM has been previously used to reconstitute lyophilized mucins without
affecting mucin viscoelasticity as measured using rheometry, suggesting
that Hepes does not interfere with the molecular organization of mucins
(19). The polystyrene particles added at a similar concentration to native
mucus do not interfere with mucus permeability (14).
Fluorescent mucins were obtained by labeling the purified mucins with
the Alexa488 fluorophore using the carboxylic acid succinimidyl ester
amine-reactive derivatives (Life Technologies Corporation, Grand Island,
NY). Mucins (4 mg/mL) were mixed with the dye in a carbonate-bicarbon-
ate buffer (0.2 M, pH 8.5) at a protein/dye mass ratio of 1:40 for 1 h
at room temperature. The excess dye was eliminated through multiple
concentration-dilution cycles by centrifuge filtering (Pall Corporation,
Port Washington, NY, 10 kDa MWCO).Biophysical Journal 105(6) 1357–1365Preparation of peptides
Peptides were synthesized by the Koch Institute Biopolymers and Prote-
omics Facility at MIT (Cambridge, MA). During synthesis, each peptide
is labeled with one fluorescein molecule at the N-terminus. The synthesized
peptides were desalted to remove trifluoroacetic acid remaining as a
byproduct of the synthesis process using a PD MiniTrap G-10 (GE Health-
care, Piscataway, NJ) size exclusion column with 20 mM NaCl/20 mM
Hepes at pH 7 as the equilibration and elution buffers. The eluted fractions
at pH 7 are retained for experiments. The concentration of the purified pep-
tide was determined by the absorption of the fluorescein-labeled peptides at
the fluorescein excitation wavelength of 490 nm compared to a concen-
tration standard with free fluorescein dye. Peptides were used at a final
concentration of 4 mM in the permeability experiments. Identical concentra-
tions of NaCl and Hepes were used for creating the mucin barrier and the
peptide flow on-chip to avoid ionic concentration gradients, which could
affect the barrier permeability properties.Microfluidic device fabrication
Soft polymer microfluidic device fabrication techniques were used to fabri-
cate the microfluidic devices (29). Two silicon wafer masters were created:
one for the peptide flow and mucin channels, and another for the microflui-
dic valve. For the flow and mucin channels wafer, the microchannel features
were defined in AZ4620 positive photoresist (Clariant Corporation, Somer-
ville, NJ) coated onto a silicon wafer to a height of 30 mm, followed by
baking on a hot plate for 1 h at 150C for photoresist reflow to create the
rounded channel profile needed for microfluidic valve activation (30). For
the valves wafer, valve features were defined in SU8 negative photoresist
(Microchem Corporation, Newton, MA) coated onto a silicon wafer to a
height of 20 mm. Both finished wafers were treated with perfluorinated
trichlorosilane (T2492-kg, United Chemical Technologies, Bristol, PA) in
a desiccator jar for at least 4 h to prevent irreversible RTV bonding to the
wafer.
RTV prepolymer and curing agent (RTV615, Momentive Performance
Materials, Albany, NY) were mixed in a 1:5 (w/w) ratio, degassed for
1 h inside a desiccator jar, and poured onto the flow channels wafer to a
height of ~1 cm. RTV prepolymer and curing agent were also mixed in a
1:20 (w/w) ratio, degassed for 1 h, and spun onto the valves wafer at
1200 rpm for 60 s, resulting in an RTV thin layer of ~60 mm. The two
wafers were baked separately on hotplates at 95C for 45 min, after which
the partially cured RTV structures were peeled from the flow channels
wafer and aligned to the valve features on the valves wafer with the aid
of a dissection microscope. The valves wafer with the bonded flow channel
RTV structures was placed on a hotplate at 95C for at least 24 h to cure the
monolithic RTV flow channels and valves structure. These structures were
then peeled from the wafer and cut into individual devices. Finally, access
holes for fluid connections to the sample channels are punched, and the
RTV structure was bonded to a glass slide after treatment with oxygen
plasma to complete the device.
The bonded device is mounted onto an inverted epifluorescence micro-
scope (IX-71, Olympus American, Central Valley, PA). Pipette tips with
200 mL volume (USA Scientific, Ocala, FL) were modified by cutting
off a 2 mm section from the tip and then inserting it into the punched
RTV access holes to function as fluid reservoirs. A 3 mL plastic syringe
is connected through PTFE tubing (IDEX Health & Science LLC, Oak
Harbor, WA) to the valve channel reservoir, allowing pneumatic control
of the microfluidic valve. The reconstituted mucin sample is loaded
into a 50 mL volume glass syringe (model 1705, Hamilton Company,
Reno, NV) and connected to the device through a 15 cm length of fused
silica tubing (Fused Silica Tubing TSP 0.36 mm outer diameter/100 mm
inner diameter, Polymicro Technologies, Phoenix, AZ). Peptide flow rates
were set using gravity driven flow by filling an inlet and outlet peptide
reservoir to uneven heights. The same flow rate was used for all
experiments.
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procedure
Fig. 1 a shows the top-down geometry of the microfluidic device used to
form the mucin barrier. The device design consists of a wide main channel
(200 mm wide by 30 mm high) with a side channel (75 mm wide by 30 mm
high). The main channel contains a push down style (30) microfluidic valve
~450 mm from the intersection of the main and side channels. This valve
may be reversibly opened or closed based on applied air pressure inside
the valve channel. To operate the device, the mucin sample is pumped
into the device and fills both the main channel and the side channel while
the valve is open. In step 2, the microfluidic valve is closed, and a buffer
solution is flowed by gravity into the flow channel and out the top of the
main channel, flushing away mucins in its flow path and creating a
mucin-water interface. We define the location of this interface to x ¼ 0.
In step 3, the buffer flow in the side channel is replaced by a flow of the
fluorescent peptide molecules. These peptides then diffuse into the mucin
barrier across the water-mucin interface.Data acquisition and analysis
Fluorescent images of peptide transport into themucin barrier were obtained
at 10 s intervals. To prevent photobleaching, the excitation light-emitting
diode of the microscopy system was programmatically set to only turn onFIGURE 1 Microfluidic device enables mucin barrier formation on-chip.
(a) A mucin sample initially filling both the flow and mucin channels (step
1, top-down view) is shaped into a layer of fixed width between a buffer flow
and a microfluidic valve inside the mucin channel (step 2). Fluorescent pep-
tides flushed into the device arrive at the mucin barrier surface and transport
into the mucin barrier over time. (step 3) (b) Formation and stability of the
mucin barrier on-chip is assessed using fluorescently labeled mucins,
showing that the mucin barrier surface interface is stable over time. (c)
Mucins are gradually lost from the mucin barrier over time, likely due to
surface fluid shearing. We limit the duration of permeability measurements
to 10 min to ensure that a majority of the initial mucin quantity remains
inside the mucin barrier during the experiment. n ¼ 3 devices.during active exposure. From each fluorescence image, the fluorescence pro-
file of the peptide is extracted across the midline of the mucin channel (see
the dotted line in Fig. 2 b), subtracting the backgroundfluorescence, and con-
verted to a concentration profile assuming linearity between concentration
and fluorescence as demonstrated in previousmicrofluidic experiments (31).
Each peptide accumulation into the mucin barrier is calculated by inte-
grating the cross-sectional peptide concentration profile as a function of x
for the range of x values covering thewidth of the mucin barrier and dividing
by thewidth of themucin barrier. This calculates the average peptide concen-
tration accumulated inside themucin barrier over the duration of experiment.
All error bars and5 error values given in the text and figures represent
one standard deviation. A minimum of three experiments were conducted
for each data point.RESULTS AND DISCUSSION
Microfluidic device enables the formation of a
mucin barrier on-chip
The passage of a particle across the mucus barrier consists
of a series of events, including partitioning (or entry) into
the mucus barrier, translocation through the barrier, and
exit from the barrier. Several studies have used multiple par-
ticle tracking techniques (10–20) or fluorescence recovery
after photobleaching (32,33) to measure the diffusivity of
particulates inside the mucus gel. These techniques reveal
important information about the mobility of particles inside
the mucus barrier, but they lack information about a parti-
cle’s ability to enter the mucus barrier. This information is
crucial to predict overall transport through any barrier. To
address this technical limitation we have created a micro-
fluidic system with which we can generate a mucin barrier
on-chip, and quantify particles entry into, and transport
across, the mucin barrier (Fig. 1 A).
The mucin sample is filled into the microfluidic device
(Fig. 1 a, step 1, top-down view) and shaped into a barrier
of ~250 mmwidth, using buffer flow (left) and a microfluidic
valve (right) (step 2). To determine the stability of the on-chip
barrier, we spiked the mucin sample with fluorescently
labeledmucins andmonitored both the presence of themucin
barrier interface and the fluorescence intensity of the barrier
over time (Fig. 1 b). This experiment revealed that the inter-
face of the mucin barrier remains stable over the entire time
of observation. However, over time, the concentration of
mucins inside the barrier appears to decrease (Fig. 1 c), likely
due to fluid shearing at themucin barrier interface. This shed-
ding process also occurs in the natural mucus layer in vivo
due to enzyme action and fluid shearing (34), and could
provide valuable information, but it also complicates the
quantification of transport. Hence, to avoid this complication
we limit the duration of the transport experiments to 10 min,
where we observe a minimal shedding of the barrier.Mucins form a charge selective permeability
barrier to peptides
To study the effect of detailed spatial arrangements and
combination of charge on mucosal passage, we need toBiophysical Journal 105(6) 1357–1365
1360 Li et al.test substrates that can be equipped with defined heteroge-
neous spatial surface configurations. This is not easy to
achieve with nanoparticles, hence, we explored if short pep-
tides, which are easy to manipulate and allow for a system-
atic variation of amino acid arrangements, may serve as
alternative reporters for probing mucin-barrier selectivity.
We prepared two peptides with uniform charge: the cationic
peptide consisted of 10 positively charged lysine residues,
each separated by one alanine residue; and the anionic pep-
tide consisted of 10 negatively charged glutamic acid
residues, each also separated by one alanine residue. Each
peptide was labeled with one fluorescein molecule for visu-
alization (Fig. 2 a).
We quantified the transport of the cationic and anionic
peptides into a barrier consisting of 0.5% mucins (w/v;FIGURE 2 Mucins form a charge selective permeability barrier to peptides. (a
and spatial charge distributions are used as probes to test mucin barrier permeab
series of fluorescence peptides entering a 0.5% (w/v) mucin barrier at 20 mM
anionic peptides. (c) Fluorescence images are analyzed across the midline o
Fig. 2 b) to obtain peptide concentration profiles in the absence and presence
the presence of mucins but are shaped identically when mucins are absent, de
peptides.
Biophysical Journal 105(6) 1357–1365reconstituted in 20 mM NaCl/20 mM Hepes) (Fig. 2, b
and c). The peptides were introduced into the microfluidic
channel at a concentration of 4 mM. At this concentration,
the peptides represented a minority of the charge in the sys-
tem and hence, would not significantly change the ionic
environment of the mucin barrier. Fluorescence micro-
graphs and the peptide transport profiles are shown in
Fig. 2, b and c. Fig. 2 c indicates that the anionic peptide
forms a decreasing concentration gradient through the
mucin barrier that looks similar to the profile established
in the absence of mucins. This result suggests a near lack
of interactions between this peptide and the mucins. This
conclusion was confirmed by quantifying the average con-
centration of the peptide that accumulated inside the mucin
barrier over 10 min (see Fig. 3 b). This quantification shows) A suite of peptides of equal molecular weight but with different net charge
ility. Note the block and alternate peptides are molecular isomers. (b) Time
NaCl ionic strength show different transport behaviors of the cationic and
f the microfluidic mucin channel (marked by dotted arrow labeled x in
of 0.5% (w/v) mucins. The peptide profiles of the two peptides differ in
monstrating that mucins are responsible for the selective transport of the
Spatial Charge Modulates Mucin Barrier Transport 1361that transport of the anionic peptide was reduced by 12% in
the presence of the mucins (from 3.3 5 0.2 mM to 2.9 5
0.1 mM).
The situation was different for the cationic peptide,
whose concentration rose to a peak value at the entry of
the mucin barrier, before sharply dropping off. (Fig. 2 c)
This peak is indicative of attractive interactions between
the cationic peptide and negatively charged mucins, or
possible mucin barrier surface partitioning effects such as
Donnan partitioning (35,36) that would enhance local pep-
tide concentration. The quantification of accumulation re-
veals that the concentration of cationic peptide inside the
mucin barrier was reduced by 61% compared to the same
region in the mucin-free control (Fig. 3 a, from 3.3 5
0.1 mM to 1.35 0.1 mM), showing that the mucins strongly
hinder free diffusion of the cationic peptide. Taken
together, these results confirm previous studies that show
particulate net charge strongly influences transport through
the mucin barrier (20). Hence, we conclude that short pep-
tides, despite their small size, reflect critical transport prop-
erties observed with uniformly coated nanoparticles and
hence, are useful reporters for further probing mucin
permeability mechanisms.FIGURE 3 Specific spatial distributions of negative and positive surface charg
20 mM. Quantification of peptide accumulation inside the mucin barrier and in
strongly reduced, while anionic peptide transport was only marginally reduced
blocks (5 amino acids each) reach higher concentrations in the mucin barrier c
promote transport of these peptides. (d) Transport of the alternate peptide,
change in transport rate. This indicates that the detailed charge distribution is cri
Material)A combination of negative and positive surface
charge results in accelerated peptide transport
Having confirmed the selective transport of peptides based
on charge, we next tested the effect of combining positive
and negative charges within the same peptide. For this
experiment we generated block peptides, which consist of
five positively charged amino acids followed by five nega-
tively charged amino acids, with alanine residue spacers
interspersed between the charged amino acids (Fig. 2 a).
Transport of the block peptide was measured using the
microfluidic system under the same conditions as in Fig. 2
and Fig. 3, a and b.
Because half of the block peptide is positively charged
and the other half is negatively charged, it is tempting to
speculate that its transport rate would be the additive
average of the cationic and anionic peptide transport rates.
However, Fig. 3 shows that this is not the case. Instead,
the combination of positive and negative surface charge
leads to enhanced transport compared to either surface
charge in isolation: The concentration of the block peptide
that entered the mucin barrier amounted to 300% of
the concentration reached by the purely cationic peptidee can accelerate peptide transport into a mucin barrier at an ionic strength of
mucin-free buffer after 10 min. (a and b) Cationic peptide transport was
by the presence of mucins. (c) Peptides composed of cationic and anionic
ompared to free diffusion in the buffer control, suggesting that the mucins
a molecular isomer of the block peptide, shows no mucin dependent
tical for the transport properties of the peptide. (Movie S1 in the Supporting
Biophysical Journal 105(6) 1357–1365
1362 Li et al.(4.0 5 0.1 mM and 1.3 5 0.1 mM, respectively; Fig. 3, a
and c), and to 140% of the concentration reached with
the purely anionic peptide during the same time (2.9 5
0.1 mM; Fig. 3 b). Fig. 3 c also shows that the block peptide
accumulated to a higher concentration inside the mucin
barrier than inside the mucin-free control chamber (4.0 5
0.1 mM with mucins vs. 3.4 5 0.1 mM without mucins,).
Together, these results suggest that the transport of the block
peptide is enhanced by the presence of the mucins, whereas
the transport of both the cationic and anionic peptides is
slowed by the mucins. This observation implies that the
mucins may facilitate the transport of heterogeneously
charged substrates, although hindering the transport of uni-
formly charged substrates.
The finding that combined positive and negative surface
charges can lead to facilitated transport in mucin environ-
ments has important in vivo implications. Viruses contain
combinations of positive and negative surface charges that
may modulate interactions between the particle and the
mucosal barrier (22,37). Soluble proteins such as those
secreted by bacteria also contain heterogeneous surface
charges, which may have evolved to interact with the mucus
barrier (21). Drug and gene carriers may also be multifunc-
tionalized with positive and negative charges to control
transport and targeting in the mucus barrier.
We speculate that several mechanisms contribute to the
nonadditive selective transport effects of the block peptide.
For example, particle charge can dramatically alter the par-
titioning of a substrate into a solution/gel interface via the
Donnan/Boltzmann partitioning factor (35,36). This parti-
tioning can, in principle, accelerate transport for net-posi-
tively charged peptides and slow transport of negative
particles into a gel composed of negatively charged poly-
mers such as mucins. At the same time, if positive charge
on the particle leads to binding to mucins, the resulting
diffusion-reaction kinetics can dramatically slow transport
of particles through the mucin layer, despite Donnan parti-
tioning. Both mechanisms may interact in complex ways
to produce the selective permeability effect we observed
among the cationic, anionic, and block peptides. In the
future, experimental methods and theoretical models (38)
that independently quantify the effects of partitioning, bind-
ing, and the resulting transport kinetics may be adapted to
mucin materials and to the microfluidics system to quantify
the relative effects of each mechanism component, and to
determine the relative quantities of bound and free peptides
in the mucin barrier.Spatial charge distribution influences peptide
transport
Having established that the combination of positive and
negative charges can result in nonadditive transport effects,
we now asked whether the detailed spatial arrangement of
surface properties would influence permeability into aBiophysical Journal 105(6) 1357–1365mucin barrier. This question is important because the spatial
arrangement of positive and negative charges on the sur-
faces of viruses and native proteins can also naturally vary
(21,22), and tuning of spatial charge distributions on drug
and gene carriers may provide the practical benefit of trans-
port and targeting control in the mucus barrier. To determine
if spatial charge configuration influences permeability prop-
erties of the mucin barrier, we measured the transport of a
peptide, which contains the identical amino acids as the
block peptide but arranged in an alternating sequence, as
opposed to separate blocks. (Fig. 2 a) Fig. 3, c and d, shows
that transport of the alternate peptide differed from that of
the block peptide in two measurable ways: First, its trans-
port profile into the mucin barrier was monotonically
descending, without a discernable peak as was observed
for the block peptide. Second, its accumulation rate was
unaffected by the presence of mucins (3.25 0.1 mM inside
a mucin barrier vs. 3.35 0.2 mM in the absence of mucins).
These differences between the transport profiles and trans-
port rates of the block and alternate peptides show that the
mucin barrier can distinguish the spatial configuration of
charged residues on a nanometer length scale, and that the
transport behavior through the mucin barrier cannot be
predicted by net charge of a substrate alone.The ionic environment of the mucin barrier
regulates selective permeability
The ionic strength of the mucus barrier varies in different
anatomical locations (39), is altered by the menstrual cycle
(40), and becomes dysregulated in diseases such as cystic
fibrosis (41). The pH of mucus also varies from very acidic
in the stomach (42) to neutral in the respiratory airways (43)
and cervix (44). Such differences in the ionic strength and
environment of the mucus layer have previously been pro-
posed as a method used by the body to rapidly tune the
selective permeability function of the mucus barriers (19).
This background and our findings that charge composition
and configuration strongly influence transport through
mucin gels led us to test if altered ionic strength may affect
selective peptide transport. We varied the NaCl concentra-
tion in the mucin samples and measured the resulting trans-
port of the suite of four peptides used previously. At high
ionic strength (200 mMNaCl), the cationic peptide accumu-
lated to a ninefold higher concentration compared to at low
ionic strength (5 mM NaCl; from 0.4 5 0.1 mM at 5 mM
NaCl to 4.05 0.2 mM at 200 mM NaCl; Fig. 4 a). For com-
parison, the anionic peptide only enriched 0.2 fold at
200 mMNaCl compared to the low ionic strength conditions
(Fig. 4 a). Hence, ionic strength strongly influences trans-
port of the cationic peptide, whereas the anionic peptide
remains largely unaffected.
This series of experiments also revealed that the transport
rate for the block peptide was highest at an intermediate
ionic strength of 20 mM NaCl (4.0 5 0.1 mM), compared
FIGURE 4 The ionic strength of the mucin barrier can regulate its selective properties. (a) Increasing ionic strength within the mucin barrier significantly
increases penetration and transport of the cationic (ninefold increase in accumulation from 5 to 200 mM ionic strength), but only marginally increases trans-
port of the anionic peptide. (b) Unlike the uniformly charged cationic and anionic peptides whose transport rates increased monotonically with ionic strength,
the transport rate of the block peptide was highest at the intermediate ionic strength of 20 mM NaCl. The transport rate of the alternate peptide was not
significantly affected by ionic strength, demonstrating that the influence of ionic strength on peptide transport depends on spatial distribution of change.
(Movie S2 and Movie S3) (c and d) The transport rates of the individual peptide species relative to one another depend on the surrounding ionic strength.
Hence, charge polarity and distribution may be tuned to maximize transport into mucus barriers at different anatomical locations with varying ionic
environments. n R 3 for each peptide and ionic strength combination.
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200 mM NaCl (Fig. 4 b). Hence, although transport of
cationic and anionic peptides into the mucin barrier mono-
tonically increased with ionic strength, the block peptide
showed maximal transport at an intermediate value. The
alternate peptide, in contrast, was not measurably affected
by ionic strength and accumulated to 3.1 5 0.2 mM at all
three salt concentrations (Fig. 4 b). Together, these results
suggest that the influence of ionic strength on transport
not only depends on the type of charge present in the pep-
tide, but also on its detailed arrangement. This implies
that the charge polarity and distribution can be optimized
to maximize transport into a mucin barrier at different
mucus ionic environments: At low ionic strength (5 mM
NaCl), the anionic and alternate peptides transported fastest,
at intermediate ionic strengths (20 mMNaCl) the block pep-
tide transported most effectively, and at high ionic strength(200 mM NaCl) the cationic peptide accumulated most
effectively (Fig. 4, c and d).
Taken together, our findings have important physiological
implications. For example, they suggest that pathogens such
as certain viruses may adopt their surface properties to tune
interactions with mucins and thereby perfect transport
through mucus barriers at certain anatomical locations. In
addition, our results imply that drug and gene carriers
may be equipped with specific surface charge configurations
to optimize their interactions with the mucins in mucus bar-
riers of varying ionic strength or pH arising from diseases
such as cystic fibrosis and gastric ulcers. In the future, our
experimental system can be used to probe other parameters
relevant for permeability, such as hydrophobicity. More-
over, different types of mucins such as from lung or cervical
mucus, as well as additional mucus components including
lipids, DNA, antibodies, and antimicrobial peptides can beBiophysical Journal 105(6) 1357–1365
1364 Li et al.studied to understand the mechanisms of the mucus barrier
permeability in more detail. The microfluidic system pre-
sented here also enables the study of small volumes of pri-
mary native mucus, which will be valuable to correlate
permeability changes to mucosal diseases.SUPPORTING MATERIAL
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